Founded in 2021, Spear Bio is an innovative leader in providing scalable solutions for ultra-sensitive protein biomarker measurements. Spear Bio's proprietary technology, Successive Proximity Extension Amplification Reaction (SPEAR), employs a unique 2-factor authentication mechanism to precisely measure protein biomarkers at attomolar level from sub-microliter sample volume. Spear Bio is focused on leveraging its technology's unprecedented sensitivity to transform protein research and early disease diagnosis.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/29/24 | $45,000,000 | Series A |
Bio-Techne CDH Investments Foresite Capital Maverick Ventures Yonjin Capital | undisclosed |
